Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. Lakshmaiah, K. C., Jacob, L. A., Aparna, S., Lokanatha, D. & Saldanha, S. C. Epigenetic therapy of cancer with histone deacetylase inhibitors. J Cancer Res Ther. 10, 469–78 (2014).
2. Barneda-Zahonero, B. & Parra, M. Histone deacetylases and cancer. Mol Oncol. 6, 579–89 (2012).
3. Parbin, S. et al. Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer. J Histochem Cytochem. 62, 11–33 (2014).
4. Khan, O. & La Thangue, N. B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol. Cell. Biol. 90, 85–94 (2012).
5. Lachenmayer, A. et al. Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J. Hepatol. 56, 1343–1350 (2012).
Cited by
60 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献